PENTETATE ZINC TRISODIUM

Electrolyte / Mineral

Brand names: Pentetate zinc trisodium

Pregnancy: Category BIntravenous, Respiratory (inhalation)

Mechanism of Action

12.1 Mechanism of Action Zn-DTPA forms stable chelates with metal ions by exchanging zinc for a metal of greater binding capacity. The radioactive chelates are then excreted by glomerular filtration into the urine. In animal studies, Zn-DTPA forms less stable chelates with uranium and neptunium in vivo resulting in deposition of these elements in tissues including the bone. Zn-DTPA treatments are not expected to be effective for uranium and neptunium. Radioactive iodine is not bound by DTPA.

Indications

1 INDICATIONS AND USAGE Zn-DTPA is indicated for treatment of individuals with known or suspected internal contamination with plutonium

americium

or curium to increase the rates of elimination. ( 1 )

Contraindications

• 4 CONTRAINDICATIONS None. None ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS Nebulized chelation therapy may be associated with exacerbation of asthma
The risk for depletion increases when Zn-DTPA is administered over several months
3 Risks to Care-takers Radioactive metals are known to be excreted in the urine, feces, and breast milk

Known Side Effects

8 documented side effects by frequency

Drug Not Working

>10%

Shortness of Breath

0.1-1%

Abdominal Pain

0.1-1%

Joint Pain

0.1-1%

Weakness

0.1-1%

Back Pain

0.1-1%

High Blood Pressure

0.1-1%

Chest Pain

0.1-1%

Community Discussions

No community discussions found for PENTETATE ZINC TRISODIUM yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous, Respiratory (inhalation)